will hims stop selling semaglutide Tumbles 19% After CEO Says It's Phasing Out Weight Loss Copies Novo is suing Hims &

Any eligible person can join the GLP-1 Care Track, no matter the stage of the journey they are in, as the program's expanded purpose is not just for discontinuation

After adjusting for residual confounding, the difference in weight loss between those receiving tirzepatide vs semaglutide was 2.0% (95% CI, 2.1% to 1.8%) at 3 months, 3.2% (95% CI, 3.5% to 3.0%) at 6 months, and 5.1% (95% CI, 5.8% to 4.3%) at 12 months

Evidence remains incomplete, so treatment plans should be individualized

Understanding this timeline helps set realistic expectations and identify whether your current dose is working or needs adjustment

Retatrutide Phase 2 and Phase 3: breaking records Retatrutide entered the picture with Phase 2 trial data that immediately captured attention

(September 2020)